Prevention of contrast-induced nephropathy with atorvastatin in patients with acute myocardial infarction undergoing elective percutaneous coronary intervention
10.3760/cma.j.issn.1671-7368.2011.06.019
- VernacularTitle:阿托伐他汀对急性心肌梗死择期冠状动脉介入治疗患者造影剂肾病的防治作用
- Author:
Xianping HUA
;
Ruixia WU
;
Yong YANG
;
Zheng CAO
;
Bin CHEN
;
Pingying CHEN
- Publication Type:Journal Article
- Keywords:
Nephrosis;
Anticholesteremic agents
- From:
Chinese Journal of General Practitioners
2011;10(6):422-424
- CountryChina
- Language:Chinese
-
Abstract:
The study intended to evaluate the effect of high-dese atorvastafin on serum high sensitive C-reactive protein (hs-CRP) and renal function in patients with acute myocardial infarction undergoing elective pereutancous coronary intervention ( PCI ). One hundred and sixty seven patients were randomly divided into two groups: in test group (n =84) patients received oral atorvastatin 80 mg/d and in control group (n = 83) patients received atorvastatin 20 mg/d, the medication in both groups was lasted for 7 days before PCL Compared to levels at 24 h before PCI, serum hs-CRP and creatinine levels at 48 h after PCI were increased in both groups ( both P < 0. 05), and glomerular filtration rate was decreased ( P < 0. 05 ). Compared to control group, serum hs-CRP and creatinine levels 24 h before PCI and 48 h after PCI in test group were significantly lower, and glomerular filtration rate was significantly higher (P <0. 05, respectively). The incidence of contrast-induced nephropathy was lower in test group than that in control group[7% (6/84) vs.18% (15/83), P <0.05]. The results indicate that high-dose atorvastatin might be effective in protecting patients with acute myocardial infarction undergoing elective PCI from contrast-induced nephropathy via inflammatory response inhibition.
